Corvus Pharma Com (CRVS)

$13.33 -0.60 (-4.31%)
Market Cap 1.21B
Revenue (ttm) 0.00
Net Income (ttm) -15.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,106,800
Avg Vol 929,652
Day's Range N/A - N/A
Shares Out 84.12M
Stochastic %K 17%
Beta 0.87
Analysts Strong Sell
Price Target $33.14

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 900 4520
Address:
901 Gateway Boulevard, Third Floor, South San Francisco, United States
lousjamsession
lousjamsession Sep. 10 at 6:38 AM
$CRVS .........
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Sep. 9 at 7:56 PM
$CRVS 🚨ALERT: price breakdown for CRVS. Are we seeing the beginning of a big drawdown? Follow the doc for the latest information.
0 · Reply
abc12332
abc12332 Sep. 9 at 6:45 PM
$CRVS Holy Hell, we are down damn near a dollar and are heading to 12’s. The timing is really odd just a day before the investor’s fireside chat. I can’t help but wonder who’s selling and why.
3 · Reply
Jellysquid1
Jellysquid1 Sep. 9 at 6:29 PM
$CRVS SMIDGING ACTIVATED! Will start buying MOORE!
1 · Reply
tradingjunk321
tradingjunk321 Sep. 9 at 6:23 PM
$CRVS Moore than before!
1 · Reply
dwsrph1
dwsrph1 Sep. 9 at 5:26 PM
$CRVS It’s All Good!
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Sep. 9 at 3:16 PM
$CRVS
0 · Reply
KingKai2020
KingKai2020 Sep. 9 at 2:31 PM
$CRVS $13.35 back in buyijg trading shares. resting orders at $13.25 and $13.15.
0 · Reply
Jellysquid1
Jellysquid1 Sep. 9 at 1:18 PM
$CRVS TOMORROW…
0 · Reply
lousjamsession
lousjamsession Sep. 9 at 12:03 PM
$CRVS
1 · Reply
Latest News on CRVS
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

Sep 3, 2026, 8:30 AM EDT - 6 days ago

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Aug 27, 2026, 7:30 AM EDT - 13 days ago

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2026

Corvus Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Earnings release: Q2 2026

Corvus Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Quarterly report: Q2 2026

Corvus Pharmaceuticals reports Q2 EPS (19c), consensus (17c)

2026-08-06T20:12:34.000Z - 4 weeks ago

Corvus Pharmaceuticals reports Q2 EPS (19c), consensus (17c)

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Aug 6, 2026, 4:01 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Corvus Pharmaceuticals Slides: Corporate presentation

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Corvus Pharmaceuticals Slides: Corporate presentation

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Jul 30, 2026, 4:01 PM EDT - 5 weeks ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Jun 9, 2026, 7:30 AM EDT - 3 months ago

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 11:20 AM EDT - 3 months ago

Corvus Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 3 months ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Corvus Pharmaceuticals Slides: FY 2026

Jun 3, 2026, 3:45 PM EDT - 3 months ago

Corvus Pharmaceuticals Slides: FY 2026

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 4:01 PM EDT - 3 months ago

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Corvus Pharmaceuticals Transcript: Study update

May 14, 2026, 1:30 PM EDT - 3 months ago

Corvus Pharmaceuticals Transcript: Study update

Corvus Pharmaceuticals Press release: Study update

May 14, 2026, 1:30 PM EDT - 3 months ago

Corvus Pharmaceuticals Press release: Study update

Corvus Pharmaceuticals Slides: Study update

May 14, 2026, 1:30 PM EDT - 3 months ago

Corvus Pharmaceuticals Slides: Study update

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

May 14, 2026, 7:00 AM EDT - 3 months ago

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

SID

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

2026-05-07T21:26:08.000Z - 4 months ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:01 PM EDT - 4 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Corvus Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 4 months ago

Corvus Pharmaceuticals Earnings release: Q1 2026

Corvus Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 4 months ago

Corvus Pharmaceuticals Quarterly report: Q1 2026

Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Corvus Pharmaceuticals Proxy statement: Proxy filing

Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Corvus Pharmaceuticals Proxy statement: Proxy filing

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Apr 23, 2026, 7:30 AM EDT - 4 months ago

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Apr 21, 2026, 7:30 AM EDT - 4 months ago

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

2026-04-17T08:45:23.000Z - 4 months ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

2026-03-13T12:16:32.000Z - 6 months ago

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Corvus Pharmaceuticals files automatic mixed securities shelf

2026-03-13T12:08:45.000Z - 6 months ago

Corvus Pharmaceuticals files automatic mixed securities shelf

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Corvus Pharmaceuticals Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Corvus Pharmaceuticals Annual report: Q4 2025

Corvus Pharmaceuticals Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Corvus Pharmaceuticals Earnings release: Q4 2025

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

2026-03-12T20:05:16.000Z - 6 months ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals Slides: Corporate presentation

Mar 12, 2026, 4:00 PM EDT - 6 months ago

Corvus Pharmaceuticals Slides: Corporate presentation

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Mar 5, 2026, 4:01 PM EST - 6 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 2:40 PM EST - 6 months ago

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 6 months ago

Corvus Pharmaceuticals Slides: Corporate presentation

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 4:01 PM EST - 6 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

2026-01-29T11:51:48.000Z - 7 months ago

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 23, 2026, 5:00 PM EST - 7 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

2026-01-22T17:30:16.000Z - 7 months ago

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

2026-01-22T13:40:42.000Z - 7 months ago

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 10:53 PM EST - 7 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

2026-01-21T13:50:38.000Z - 7 months ago

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

Corvus Pharmaceuticals announces $150M common stock offering

2026-01-20T21:10:39.000Z - 7 months ago

Corvus Pharmaceuticals announces $150M common stock offering

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 4:01 PM EST - 7 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

2026-01-20T20:30:11.000Z - 7 months ago

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:10 PM EST - 7 months ago

What made Corvus stock double on Tuesday and is it sustainable?

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

2026-01-20T17:35:42.000Z - 7 months ago

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

Corvus Pharmaceuticals Transcript: Study result

Jan 20, 2026, 8:00 AM EST - 7 months ago

Corvus Pharmaceuticals Transcript: Study result

Corvus Pharmaceuticals Press release: Study result

Jan 20, 2026, 8:00 AM EST - 7 months ago

Corvus Pharmaceuticals Press release: Study result

Corvus Pharmaceuticals Slides: Study result

Jan 20, 2026, 8:00 AM EST - 7 months ago

Corvus Pharmaceuticals Slides: Study result

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 16, 2026, 4:01 PM EST - 7 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 10 months ago

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Corvus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Corvus Pharmaceuticals Quarterly report: Q3 2025

Corvus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Corvus Pharmaceuticals Earnings release: Q3 2025

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 10 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Corvus Pharmaceuticals Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 10 months ago

Corvus Pharmaceuticals Slides: Corporate Presentation

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 31, 2025, 7:30 AM EDT - 10 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 28, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 17, 2025, 10:00 AM EDT - 10 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Oct 2, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Corvus Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q2 2025

Corvus Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q2 2025

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Corvus Pharmaceuticals Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Corporate Presentation

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

Corvus Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q1 2025

Corvus Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q1 2025

Corvus Pharmaceuticals Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Q1 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 8, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 23, 2025, 4:08 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2025, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Corvus Pharmaceuticals Annual report: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Annual report: Q4 2024

Corvus Pharmaceuticals Earnings release: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q4 2024

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 9:20 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Corvus Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Slides: FY 2025

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corvus Pharmaceuticals Transcript: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Study Update

Corvus Pharmaceuticals Press release: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Press release: Study Update

Corvus Pharmaceuticals Slides: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Slides: Study Update

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Corvus Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q3 2024

Corvus Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings release: Q3 2024

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Corvus Pharmaceuticals Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Quarterly report: Q2 2024

Corvus Pharmaceuticals Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings release: Q2 2024

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Corvus Pharmaceuticals Registration statement: Registration Filing

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corvus Pharmaceuticals Registration statement: Registration Filing

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

lousjamsession
lousjamsession Sep. 10 at 6:38 AM
$CRVS .........
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Sep. 9 at 7:56 PM
$CRVS 🚨ALERT: price breakdown for CRVS. Are we seeing the beginning of a big drawdown? Follow the doc for the latest information.
0 · Reply
abc12332
abc12332 Sep. 9 at 6:45 PM
$CRVS Holy Hell, we are down damn near a dollar and are heading to 12’s. The timing is really odd just a day before the investor’s fireside chat. I can’t help but wonder who’s selling and why.
3 · Reply
Jellysquid1
Jellysquid1 Sep. 9 at 6:29 PM
$CRVS SMIDGING ACTIVATED! Will start buying MOORE!
1 · Reply
tradingjunk321
tradingjunk321 Sep. 9 at 6:23 PM
$CRVS Moore than before!
1 · Reply
dwsrph1
dwsrph1 Sep. 9 at 5:26 PM
$CRVS It’s All Good!
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Sep. 9 at 3:16 PM
$CRVS
0 · Reply
KingKai2020
KingKai2020 Sep. 9 at 2:31 PM
$CRVS $13.35 back in buyijg trading shares. resting orders at $13.25 and $13.15.
0 · Reply
Jellysquid1
Jellysquid1 Sep. 9 at 1:18 PM
$CRVS TOMORROW…
0 · Reply
lousjamsession
lousjamsession Sep. 9 at 12:03 PM
$CRVS
1 · Reply
Mr_Predicto
Mr_Predicto Sep. 8 at 7:18 PM
$CRVS What's this coming up? Another chat/conference/PR fluff event? Great! It looks like that over bet for how many times they are going to re-hash Phase 1 data is going over 100. Longs can keep taking hits off that hopium bong, but deep down they know it will just be another potemkin display. Prediction: Here we go ahhhhhgaaaaain.
1 · Reply
tradingjunk321
tradingjunk321 Sep. 8 at 6:23 PM
$CRVS our time will come!
1 · Reply
ObserverOne
ObserverOne Sep. 8 at 2:03 PM
$CRVS so, novartis took a major egg on the face with the Avidity (RNA) acquisition. And Avidity had Phase 3 assets (which now have bombed). I really don't want to hear from the bulls how $CRVS will be acquired. Maybe in 5 years, lol.
2 · Reply
lousjamsession
lousjamsession Sep. 8 at 6:13 AM
$CRVS .....
1 · Reply
Jellysquid1
Jellysquid1 Sep. 7 at 11:57 PM
$CRVS Happy Labor Day! CRVs Will be Presenting With Cantor….😄
1 · Reply
CapitalMonk
CapitalMonk Sep. 4 at 4:24 PM
$CRVS Price: $14.49 (-1.06%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±3.24% RSI: 45.3 | Momentum: Moderate Volume: -82.1% vs avg Volatility: 3.01% Support: $13.43 | Resistance: $15.72 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
tradingjunk321
tradingjunk321 Sep. 4 at 3:37 PM
$CRVS Eventually this will come true!
1 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Sep. 4 at 2:57 PM
$CRVS down 1.4%!
0 · Reply
lousjamsession
lousjamsession Sep. 4 at 5:01 AM
$CRVS ..
1 · Reply
tradingjunk321
tradingjunk321 Sep. 3 at 10:53 PM
$CRVS 19,100,000 short, this could be epic!
1 · Reply
tradingjunk321
tradingjunk321 Sep. 3 at 10:16 PM
$CRVS Moore!
1 · Reply
tradingjunk321
tradingjunk321 Sep. 3 at 7:55 PM
$CRVS looking scrumptious 💕
1 · Reply